AI drug-discovery startup building models for molecular and antibody design
Chai Discovery applies AI to molecular and antibody design for drug discovery. It appears on both Forbes AI 50 2026 and CB Insights AI 100 2026, making it a high-signal private AI biotech gap for the tracker.
Biotech📍 San Francisco, CAFounded 2024
Current Valuation
$1.3B
as of 2026-Q2
UNICORN
QL Price
$3.3B
-12% vs last round
QuantLogix's current estimate for Chai Discovery, published 2026-09-15 — below the last disclosed round of $3.8B (2026-07).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$3.8B
2026-07
weight 0.87
Secondary market print
$2.7B
2026-06-27
weight 0.62
How this price has held up
No round has priced for Chai Discovery since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-15 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Chai Discovery, 2026-09-15 (9c50cd63e9b13768).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Chai Discovery going public?
No. Chai Discovery is private and has not filed to go public. There is no S-1 on file.
What is Chai Discovery's valuation in 2026?
Chai Discovery is valued at $1.3B as of 2026-Q2, set by its Growth (Apr 2026). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Chai Discovery filed an S-1?
No public S-1 is on file for Chai Discovery.
Can you buy Chai Discovery stock?
No. Chai Discovery is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Chai Discovery on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
CEO
Joshua Meier
Founded
2024
HQ
San Francisco, CA
Employees
Undisclosed
Total Raised
$225M
Growth
Forbes reported valuation increased from ~$150M to ~$1.3B in 15 months
IPO Status
private
Fundraising Status
Growth · 5 mo ago
privateTotal raised $225M
Secondary Market
Implied price / share
$47.97
Last round price / share
$67.66
vs last round
-29.1%
Open interest
5
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Growth
—
Apr 2026
Forbes AI 50 profile
—
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Chai Discovery — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-11. Re-checked weekly.
Talent Signal
Hiring trend
● First snapshot
trend accrues with monthly sweeps
Open roles
14
via ashby
Product-build share
57%
engineering, research, product, design
Trajectory
steady
product-led hiring — 57% of open roles build product; the rest are go-to-market and G&A.
Counted from Chai Discovery's live job board as of 2026-08-17; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
AIBiotechAI Drug DiscoveryForbes AI 50CB Insights AI 100
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2026-Q2. Refreshed quarterly.